Tomioka M, Miyazaki N, Yamamoto M, Saito Y
First Department of Surgery, Kobe University School of Medicine.
Nihon Shokakibyo Gakkai Zasshi. 1993 Mar;90(3):693-9.
We studied on the effect of combined use of CR1505 with UFT for the subcutaneously transplanted pancreatic cancer induced by BOP (N-nitrosobis (2-oxopropyl) amine) in the Syrian golden hamsters. The tumor growth in the group treated with both CR1505 and UFT was significantly inhibited compared with that in the group treated with only CR1505 or UFT. Labelling index judged by BrdU immunohistochemistry in the group with the combined use was significantly lower than that in the group with the single use. The differences of the body weights and blood analysis were not obscured in the both groups. Moreover, the concentrations of 5-FU and FT207 in tumors were not different between them. These results suggest that a new therapy of the combined use with CR1505 and UFT for the pancreatic cancer should be effective.
我们研究了CR1505与优福定联合使用对叙利亚金黄地鼠皮下移植的由BOP(N-亚硝基双(2-氧代丙基)胺)诱导的胰腺癌的影响。与仅用CR1505或优福定治疗的组相比,用CR1505和优福定联合治疗的组中的肿瘤生长受到显著抑制。联合使用组中通过BrdU免疫组织化学判断的标记指数显著低于单一使用组。两组的体重和血液分析差异不明显。此外,两组肿瘤中5-FU和FT207的浓度没有差异。这些结果表明,CR1505与优福定联合用于胰腺癌的新疗法应该是有效的。